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Osteoblast activity on collagen-GAG scaffolds is affected by collagen and GAG 
concentrations 
 
Abstract 
Optimisation of a tissue engineering scaffold for use in bone tissue engineering requires 
control of many factors such as pore size, porosity, permeability and, as this study shows, 
the composition of the matrix. The collagen and GAG content of the collagen-GAG 
scaffold variants were fabricated by varying the collagen and GAG content of the 
scaffold. Scaffolds were seeded with MC3T3 osteoblasts and cultured for up to 7 days. 
During the culture period, osteoblastic activity was evaluated by measuring metabolic 
activity, cell number and spatial distribution. Collagen and GAG concentrations both 
affected osteoblast viability, proliferation and spatial distribution within the scaffold. 
Scaffolds containing 1% collagen (w/v) and 0.2% GAG (w/v) were found to have a 
porosity of ~99%, high cell metabolic activity and number and cell infiltration up to 7 
days. Taken together, these results indicate the need to tailor the parameters of a 
biological substrate for use in a specific tissue application, in this case bone tissue 
engineering.   
 
Key Words: Scaffold composition, Porosity, Bone tissue engineering, Cell attachment, 
 Cell migration   
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Osteoblast activity on collagen-GAG scaffolds is affected by collagen and GAG 
concentrations
1. Introduction
     Collagen-glycosaminoglycan (GAG) scaffolds are currently being used in a wide 
range of applications within tissue engineering, but these scaffolds were first developed 
for use in skin regeneration and it is currently a FDA-approved dermal graft substitute [1, 
2]. To date, tissue engineering applications of the collagen-GAG scaffold have been 
concentrated in areas such as muscle, cartilage and nerve with successful nerve 
regeneration in a rat model [3-11]. These scaffolds meet a majority of the requirements 
needed for tissue engineering matrices. They are biocompatible, biodegradable with non-
toxic degradation products and have a high porosity (~99.5%) with an interconnected 
pore architecture. The high porosity and interconnectivity allows for the infiltration of 
cells, diffusion of nutrients and subsequent vascularisation. An additional advantage of 
these scaffolds is that the pore architecture can be controlled during fabrication to form 
scaffolds with a homogenous pore structure and a mean pore size that can range from 96 
to 150 µm [12]. However, tissue-specific optimisation of the collagen-GAG scaffold 
might improve the success of the construct by modifying the scaffold composition, pore 
size and mechanical properties. 
     The main constituent of the collagen-GAG scaffold is collagen, which is used 
extensively within the medical and biomedical industries since it exhibits low 
antigenicity, has excellent haemostatic and cell binding properties and is biodegradable 
[13, 14]. Glycosaminoglycans (GAGs) are negatively charged carbohydrates that are 
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common constituents of cell surfaces and extracellular matrices. Biocharacteristics of 
GAGs include the binding and regulation of growth factors and cytokines, and they are 
involved in cell adhesion, migration, proliferation and differentiation [13, 15]. It has been 
found that the attachment of GAGs to the collagen protein can increase cell proliferation 
and migration of cells through the collagen matrix. The presence of GAG in the collagen-
GAG matrix has also been found to preserve the porous lamellar structure of the matrix 
[15, 16]. Therefore, an adjustment of the amount of GAG that is contained within the 
collagen scaffold may have a dramatic effect on the consequent cellular response. A 
recent study in our laboratory found that osteogenesis can be sustained on the collagen-
GAG scaffold, with mineralisation of the scaffold after 21 days. This indicates that the 
collagen-GAG scaffold has significant potential for use within bone tissue engineering, 
even before the adaptation of the scaffold specifically for this application [17]. However, 
currently in the literature there are conflicting reports as to what effect GAG has on the 
growth of mineralisation crystals such as hydroxyapatite. Some reports indicate that it 
sequesters calcium ions and thereby prevents mineral growth [18], therefore it is 
important to evaluate GAG content in the context of bone tissue engineering.     
     While the collagen-GAG scaffold has been fabricated, designed and optimised for use 
in skin regeneration, its material content has not been varied with other specific tissue 
applications in mind. It has been well documented that the material content of any 
scaffold for tissue engineering affects the cellular behaviour on the matrix [19]. Varying 
the content of the scaffold will also affect the resultant material properties such as 
porosity, surface area and elastic modulus. Any scaffold for tissue engineering must have 
ligands available for cell adhesion, be able to support attachment and differentiation of 
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the relevant cell type, diffusion of the appropriate biochemical markers, nutrients and cell 
waste and must allow the application of mechanical and biological signals to support the 
relevant cell phenotype [20, 21]. The objective of this study was to optimise the current 
collagen-GAG scaffold for use in bone tissue engineering by varying the concentrations 
of collagen and GAG. The main component of the matrix is collagen type-I, which is the 
primary organic component of bone. By increasing the collagen concentration, this could 
encourage osteoblastic function by increasing the availability of ligands for osteoblast 
integrin binding. This would in turn, encourage osteoblast maturation, matrix production 
and consequent mineralisation [22, 23].  Specifically, we sought to determine the effect 
of varying the collagen and GAG concentrations on the following measures of 
osteoblastic activity: 1) metabolic activity, 2) attachment, 3) proliferation, and 4) spatial 
distribution within the scaffold. 
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2. Materials and Methods
2.1 Fabrication of collagen-glycosaminoglycan scaffolds
     Collagen-GAG scaffolds were fabricated as previously described using a freeze-
drying technique [12]. Briefly, the collagen-GAG suspension was produced by 
combining type I collagen, isolated from bovine tendon (Integra Lifesciences, Plainsboro, 
NJ), with chondroitin-6-sulphate, isolated from shark cartilage (Sigma-Aldrich, 
Germany), in a soluti n of 0.05 M acetic acid. The resulting solution was degassed to 
remove any air bubbles and subsequently stored at 4°C. All collagen-GAG slurries were 
freeze-dried at -40°C using a constant cooling technique [12]. After freeze-drying, the 
collagen-GAG scaffolds were crosslinked by a dehydrothermal process for 24 h at a 
temperature of 105°C in a vacuum oven at 50 mTorr (VacuCell, MMM, Germany).
     To assess the effect of varying the collagen and GAG content in the collagen-GAG 
scaffold, different scaffold compositions were varied with respect to the Standard
collagen-GAG scaffold that is currently being used clinically as a dermal substitute 
(Integra Life Sciences, Plainsboro, NJ, USA). The Standard scaffold has a collagen 
concentration of 3.6 g (0.5% w/v solution) and a chondroitin-6-sulphate (GAG) 
concentration of 0.32 g (0.1% w/v solution). The composite collagen-GAG scaffolds 
were divided into two groups: [1] Collagen Scaffold Variants, in which the amount of 
type I collagen was varied and the chondroitin-6-sulphate was kept constant and [2] GAG 
Scaffold Variants, in which the GAG content was varied and the amount of collagen was 
kept constant. The collagen scaffold variants consisted of five different collagen
concentrations: 0.25%, 0.38%, 0.5% (Standard of 3.6g), 0.75% and 1% collagen with the 
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GAG amount kept constant at 0.32 g. The GAG scaffold variants consisted of four 
different composites: 0%, 0.05%, 0.1% (Standard of 0.32g) and 0.2% GAG with the 
collagen amount kept constant at 3.6g. 
2.2 Scaffold Porosity:
Using a hollow punch, each of the collagen and GAG scaffold variants were cut into 
discs of 12.7 mm. The dry weight of each scaffold disc was determined using a mass 
balance and the height and diameter determined using vernier callipers (Krunstoffwerke, 
Radionics, Ireland) in order to assess scaffold volume. The relative density of the 
scaffolds was calculated from the dry weight and volume of each scaffold disc and the 
known density of collagen and GAG. From this, the percentage porosity was calculated 
as:
           Equation 1                Porosity (%) = (1 – scaffold / solid matrix) x 100
Results of eight measurements were averaged per scaffold variant.  
2.3 Cell culture:   
     The two groups of collagen-GAG scaffolds were subjected to cell culture to 
investigate the effects of collagen and GAG on short-term osteoblastic activity using 
established techniques [15]. MC3T3-E1 cells were cultured in standard tissue culture 
flasks using -MEM supplemented with 10% fetal bovine serum, 1% L-glutamine and 
1% penicillin/streptomycin solution (Sigma-Aldrich, Germany). The media was replaced 
every 3-4 days. Cells were removed from the base of the tissue culture flasks using a 
trypsin-EDTA solution (Sigma) and cell number was calculated using a hemacytometer. 
Page 6 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6
The resulting cell solution was centrifuged (5 min at 20°C) and re-suspended in 
supplemented media to obtain a cell suspension of 1 x 106 cells per 400 µl (or 
alternatively 2.5 x 106 per ml). 
Sections of scaffold, 1 x 2 cm (~ 4mm in height) were cut from each of the scaffold 
variants and placed into a 6-well tissue culture plate (Sarstedt Ltd, Ireland). Each 6-well 
tissue culture plate was pre-coated with 2% agarose gel (Promega, AGB Scientific Ltd, 
Ireland) to prevent cells from adhering to the tissue culture plate [24]. Each of the 
scaffolds was then seeded with 2 x 106 cells. A cell suspension of 400µl (1 x 106 cells) 
was seeded onto the surface of the dry scaffold and returned to the incubator for 10 
minutes to allow for initial cell attachment. The scaffold was then turned over and the 
previous cell seeding step repeated so that a total of 2 x 106 cells was seeded on each 
scaffold. After 10 minutes, 4 ml of supplemented media was added to each well. 
Constructs were maintained at 37°C with 5% CO2 and evaluated at 6, 24, 48 hours and 7 
days post-seeding. 
2.3 Cell metabolic activity: 
     Cell metabolic activity was evaluated using alamarBlueTM, a non-endpoint assay 
(BioSource, Belgium). Scaffolds were transferred to 6-well plates and the media replaced 
with 4 ml of supplemented -MEM containing 10% alamarBlueTM. Plates were placed on 
an orbital shaker (Biosan, Riga, Latvia) in the incubator at 37ºC and 5% CO2. After 2.5 
hours, 100 µl of the supernatant was plated in triplicate into a 96-well plate and 
absorbance of the samples was read on a spectrometer (Titertrek Multiscan, MSC, 
Ireland) at 540nm and 620nm. Percentage reduction of the alamarBlueTM solution was 
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determined according to the manufacture’s specifications. After each reading, scaffolds 
were returned to the incubator in fresh media. Cell metabolic activity was evaluated at 6, 
24, 48 hours and 7 days post-seeding. Matrices were flash frozen in liquid nitrogen, and 
stored at -80° for DNA analysis. These experiments were repeated 10 times to provide a 
sample size of n = 10.  
2.4 Cell number:
     After cell culture, constructs that were flash frozen in liquid nitrogen, were thawed 
and matrices digested in papain. Cell number was evaluated using Hoechst 33258, which 
fluorescently labels double stranded DNA (Sigma-Aldrich, Germany), according to a 
previously published protocol [25]. Measurements were taken in triplicate and 
fluorescent emission was read at 355nm excitation and 460nm emission using a 
fluorescence spectrophotometer (Wallac Victor2, PerkinElmer Life Sciences). Readings 
were converted to cell number using a standard curve.  
2.5 Histological evaluation:
     At each time point, scaffold samples were placed into a solution of 10% formalin for 
30 minutes and then processed with an automatic tissue processor (ASP300, Leica, 
Germany). All constructs were embedded in paraffin wax and sectioned longitudinally at 
a thickness of 10 µm throughout the depth of the sample using a rotary microtome (Leica 
microtome, Leica). Sections were placed in an oven at 70°C overnight to remove wax 
from the sample and stained in haematoxylin and eosin (H&E) to evaluate spatial 
distribution of cells within each of the scaffolds. 
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Statistical analysis:
     Differences between scaffold variants and different time points were analysed 
statistically using a repeated measures two-way ANOVA followed by the Holm-Sidak 
multiple comparisons test. Statistical significance was determined at p < 0.05. 
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3. Results
3.1 Collagen Scaffold Variants:
3.1.1 Scaffolds
     The addition of the collagen to the acetic acid for the 0.25%, 0.38% and the 0.5% 
collagen slurries was straightforward. Following the established protocol, it required a 
blending time of 4-6 hours to fully ensure that the collagen had formed a well mixed 
suspension. However, the additional amounts of collagen in the 0.75% and 1% collagen 
slurries proved to be more troublesome in obtaining a well mixed collagen suspension, 
with the 1% collagen slurry requiring up to three days blending to ensure that an even 
collagen suspension was obtained. However, even with the doubling of collagen content, 
the porosity of the collagen variants was still high, with the lowest porosity of 98.8% on 
the 1% collagen scaffold variant (Table 1) and the highest porosity of 99.5% found with 
the 0.38% collagen variant. Notably, the scaffold with the lowest amount of collagen 
(0.25%) had a reduced porosity in comparison to the Standard (0.5%) due to a loss of 
structural integrity.
3.1.2 Cell metabolic activity
     For the collagen scaffold variants, the two-way ANOVA indicated that both collagen 
concentration (p< 0.001) and culture duration (p< 0.001) had an effect on cell metabolic 
activity as recorded by percentage reduction of alamarBlueTM. Using a multiple 
comparisons test (Holm-Sidak), cell metabolic activity was found to be significantly 
higher on the 1% collagen and the 0.25% collagen scaffolds when compared to the other 
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groups, with the 1% collagen constructs displaying the highest metabolic activity (p< 
0.05) (Fig. 1). 
The 0.5%, 0.75% and 1% collagen variants displayed significant increases in 
metabolic activity at 7 days when compared to the initial 6 hour time point (p< 0.05), but 
there was no increase found on the 0.25% and 0.38% variants with time. Evaluation of 
the interaction between scaffold type and culture duration in the two-way ANOVA 
showed that culture duration affected metabolic activity differently for the collagen 
scaffold variants. 
3.1.3 Cell number
Both collagen concentration and culture duration affected cell number on each of the 
collagen scaffolds (p< 0.001). The 0.25% collagen and the 1% collagen constructs 
displayed a significantly higher cell number relative to the other collagen groups (p< 
0.05) (Fig. 2). Each collagen group was also analysed independently to examine effects 
over culture duration. It was found that the 0.25% collagen constructs was the only group 
to have a significant decrease in cell number at 7 days compared to 6 hours (p< 0.009),
demonstrating that while, in the short term, the 0.25% collagen variant may appear 
suitable for bone tissue engineering, the longer term data at day 7 demonstrates that this 
low content is unsuitable for tissue engineering applications.  
3.1.4 Cell spatial distribution 
Collagen concentration affected the spatial distribution of osteoblasts within the 
scaffold at day 7. The 0.25% and 0.38% collagen scaffolds exhibited good cell infiltration 
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but also demonstrated partially collapsed pore architecture (Fig. 3a and 3b).  This 
explains the reduced cell number found at day 7 on the 0.25% collagen variant.  A cluster 
of cells is evident on the 0.5% collagen scaffold (Fig. 3c), in which the cells are stained a 
deep purple. This is the original Standard scaffold which, as demonstrated by previous 
studies [12, 24], has a homogenous pore architecture that can facilitate cell infiltration. In 
the scaffolds with the highest collagen content (Fig. 3d and 3e), scaffolds tended to 
exhibit elongated plates of collagen, to which the cells readily adhered, and cell 
infiltration was evident throughout both of these scaffolds thus explaining the high 
metabolic activity and cell numbers on these variants.  
3.2 GAG Scaffold Variants:
3.2.1 Scaffolds  
     The addition of the GAG to the 0.05% and 0.1% GAG slurries was straightforward 
using a disperser system over 15 minutes, following the established protocol and required 
a blending time of 4-6 hours to ensure a well mixed GAG suspension. However, the 
addition of the extra GAG in the 0.2% GAG slurry had to be carried out slowly over a 
period of 1-2 hours during the blending process, since the extra amount of GAG started to 
extract the collagen out of suspension. When the porosities of the GAG scaffold variants 
was measured, the lowest porosity calculated was 99.1% on the 0.2% GAG scaffold 
variant, with the highest porosity of 99.4% on the 0% and 0.05% GAG scaffold variants, 
thus demonstrating that the addition of GAG had little effect on porosity (Table 2). 
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3.2.2 Cell metabolic activity
     For the GAG scaffold variants, the two-way ANOVA indicated that both GAG 
concentration (p< 0.001) and culture duration (p< 0.001) affected cell metabolic activity 
as recorded by percent reduction of alamarBlueTM. Using a multiple comparisons test, 
cell metabolic activity was found to be significantly higher on the 0.2% GAG scaffold 
compared to all other groups (p< 0.001) (Fig. 4). The 0% and 0.1% GAG constructs also 
displayed a significant increase in metabolic activity when compared to the 0.05% GAG 
construct (p< 0.001) which showed the lowest metabolic activity (Fig. 2). Each GAG 
group was also analysed to examine the effect of culture duration. All the GAG scaffold 
variants showed significant increases in cell metabolic activity at 7 days when compared 
to 6 hours (p< 0.001).
3.2.3 Cell Number
      When the GAG scaffold variants were analysed for cell number, the two-way 
ANOVA indicated that both GAG concentration and culture duration affected cell 
number (p< 0.013). When these constructs were analysed with a multiple comparisons 
test, the 0% GAG constructs were found to have the highest cell number relative to all 
other GAG groups (p< 0.003) (Fig. 5). The 0.2% GAG constructs also displayed 
increased cell numbers when compared to 0.05% and 0.1% GAG scaffolds (p< 0.05). 
Each of the GAG groups were also analysed to examine the effect of time and the 0% 
GAG construct was the only GAG group to have a significant decrease in cell number at 
7 days compared to 6 hours (p< 0.018). This demonstrates that while initial attachment is 
high, this variant does not appear to support osteoblast activity in the longer term.
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3.2.4 Cell Spatial Distribution
     H&E staining of the GAG scaffold variants demonstrated that in the 0% and 0.05% 
GAG variants (Fig. 6a and 6b), cells were found primarily on the surface of the construct, 
with little cell infiltration to the centre of the scaffold. A comparison of pore architecture 
between the two scaffolds show that while the 0.05% GAG scaffold retained its open 
pore architecture, the 0% GAG scaffold had partially collapsed pores. The 0.1% GAG 
scaffold as shown in Figure 6 (c) displays a cell cluster within the scaffold and an open 
pore architecture. The most extensive cell infiltration was found on the 0.2% GAG 
scaffold variant (Fig. 6d), with cells readily attaching throughout the construct.         
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4. Discussion
     Scaffolds for bone tissue engineering must facilitate cellular attachment and migration
followed by bone matrix formation and mineralisation. The collagen-GAG scaffold has 
been used in many laboratories and with many different cell types including fibroblasts, 
chondrocytes, neural cells and keratinocytes [8, 9, 17, 26]. However, it was first 
developed and optimised for use in skin regeneration by Ioannis Yannas in MIT 30 years 
ago [36]. This was the first time that a scaffold had been used to induce regeneration of 
an organ, namely skin, and marks the first work of a field that later became known as 
tissue engineering. This collagen-GAG scaffold consequently received FDA approval in 
1996 and has been used successfully as a clinical dermal graft substitute. However, the 
composition of the collagen-GAG scaffold has never been optimised for use in bone 
tissue engineering. The goal of this study was to optimise the scaffold for use in bone 
tissue engineering by varying the amounts of collagen and GAG to maximise osteoblast 
activity. Some studies have indicated that collagen type-I can affect integrin binding, 
expression of the osteoblastic phenotype and the formation of a mineralised matrix [27]. 
Other studies have shown that GAGs can interfere with mineral growth during 
osteogenesis.  Therefore, it is important to evaluate the effects of both collagen and GAG 
content in the context of bone tissue engineering.  While parameters such as pore size and 
permeability of the collagen-GAG scaffold have been actively investigated in relation to 
bone tissue engineering [24, 28], this study sought to investigate the osteoblastic response 
of varying the composition of the collagen-GAG matrix.
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     The scaffold variants were divided into separate collagen groups (0.25%, 0.38%, 
0.5%, 0.75% and 1% w/v) and GAG groups (0%, 0.05%, 0.1% and 0.2% w/v) and the 
cell responses investigated by measuring metabolic activity, cell number and spatial 
distribution. Metabolic activity and cell number were highest in the 0.25% and 1% 
collagen variants, surpassing that of the Standard 0.5% collagen variant which was the 
lowest both in metabolic activity and cell number. The 0.2% GAG scaffold variant 
supported the highest metabolic activity with widespread cell infiltration. The 0% GAG 
variant provided the highest cell number, but an analysis of histological images showed a 
partially collapsed pore architecture, indicating that the cells may become trapped in the 
collagen over time. Taken together, these results indicate that osteoblastic response is 
significantly affected when both collagen and GAG content is altered and demonstrates 
that a scaffold containing 1% collagen and 0.2% GAG is optimal for use in bone tissue 
engineering. 
     The results of this study are supported by the techniques used during the experimental 
period. Scaffold fabrication followed an established constant cooling freeze-drying 
technique that creates a well interconnected and porous scaffold [12]. The high surface 
area and porosity allow for the infiltration of cells into the centre of the scaffold and 
diffusion of nutrients and waste both in and out of the construct. A significant advantage 
of the collagen-GAG scaffold over other scaffold types is that as a natural polymer, it is 
highly bioactive and the high porosity and interconnected pore structure is greatly 
conducive to angiogenesis.  The porosity of the collagen and GAG variants was measured 
individually and calculations illustrate that even with the doubling of collagen and GAG
content, a porosity of ~99% is still maintained (Table 1). Other tissue engineering 
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scaffolds made from materials such as ceramics (e.g. tri-calcium phosphate and 
hydroxyapatite) or synthetic polymers (e.g. PLGA and PLLA), frequently experience a 
loss in cell viability due to reduced bioactivity, a low porosity and experience necrosis 
when implanted in vivo, particularly in the centre of the construct due to reduced 
diffusion of nutrients and limited vascularisation.
     Osteoblast attachment is regulated by integrins which link the osteoblast to ligands on 
the underlying extracellular matrix (ECM) [30, 31]. Attachment to the ECM occurs in 
two phases: 1) the attachment phase which occurs almost immediately using 
physiochemical linkages such as ionic and van der Walls forces and 2) the adhesion 
phase which occurs in the longer term using specific proteins to adhere the cells to the 
underlying ECM. These proteins interact with membrane and cytoskeletal proteins which 
then regulate signal transduction and gene expression [38]. Disruption of the integrin-
ligand interface may lead to impaired osteoblast maturation [29, 30]. Since collagen type-
I is a major component of bone extra-cellular matrix, the increase in collagen content in 
the scaffolds should lead to an increase in cell attachment and, therefore, cell activity by 
providing more ligands available for osteoblast binding. Our results support this 
hypothesis. Scaffolds with the lowest collagen content (0.25%) as well as the highest 
collagen content (1%) had the highest metabolic activity and cell number. The 
unexpected high metabolic activity and cell number on the 0.25% collagen scaffold may 
be explained by the increased surface area of the scaffold when it was seeded.  The 
0.25% scaffold lost its 3D integrity and spread across the floor of the well when seeded 
with the cell suspension and consequently behaved in a more gel-dependant manner when 
in culture. This loss of structural integrity temporarily increased the surface area leading 
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to more rapid attachment sites for the osteoblasts. However, as the cell mediated 
contraction of the scaffold began and increased over time [8, 11, 32], this lead to a 
decreased scaffold area available to the osteoblasts and therefore decreased the long-term 
attachment sites. This also explains the reduced porosity measured for the 0.25% scaffold 
in comparison to the Standard despite the lower collagen content. The greatest reduction 
in scaffold size was found on the 0.25% collagen scaffold variant and this is supported by 
the reduction of 24% in cell number on the 0.25% collagen variants and a reduction of 
16% cell number on the 0.38% constructs at 7 days when compared to 6 hours. Thus, 
while the lower content scaffolds may exhibit high cellular activity and cell infiltration in 
the short term (up to 48 hours), in the longer term they are not adequate for bone tissue 
engineering.  
     The GAG scaffold variants were also subjected to the same experimental conditions to 
investigate the effect of glycosaminoglycan content on short-term osteoblastic activity. 
GAGs have been found to amplify the biochemical and biomechanical properties of 
scaffolds when combined with collagen by affecting scaffold properties such as water 
retention and compressive strength as well as cell signalling with respect to cell adhesion, 
migration and differentiation of cells [13, 15, 16]. Studies have shown that with the 
addition of GAG to collagen scaffolds, regenerative responses are more favourable than 
those induced by collagen alone, by altering the foreign-body reactions and inflammation 
processes. Furthermore, in vivo the addition of GAG to collagen matrices tends to reduce 
the degradation rate of scaffolds and also allows the preservation of the porous 
architecture [13, 15]. We found that by varying the GAG concentrations, metabolic 
activity, cell number and cell infiltration were affected. The 0.2% GAG construct had the 
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highest cell metabolic activity and cell infiltration above all the other GAG scaffolds. 
This is supported by previous studies by Piper et al [13], showing that preparation of 
collagen matrices with GAG allows the GAG to interact with cells as well as increasing 
the water-binding capacity of the matrix. The increased water-binding capacity of the 
matrix preserves the porous structure and allows for diffusion of nutrients and waste 
through the scaffold, which is supported by the high porosity measurements for all of the 
GAG scaffold variants. Total cell number was found to be the highest on the 0% GAG 
scaffold variant relative to all other GAG groups; however, while the 0% GAG variant 
had the highest cell number, histologically the scaffold did not demonstrate complete
infiltration of cells into the matrix. During the cell culture period it also demonstrated 
collapsed pore architecture, indicating that cells may become trapped within this scaffold 
during culture. This is supported when attachment rates were analysed over time showing 
a reduction of 24% in cell number on the 0% GAG construct at 7 days compared to 6 
hours, while cell number on all other GAG scaffolds remained constant over the culture 
duration. 
One surprising result from this study is that the Standard collagen-GAG scaffold used 
for skin regeneration (0.5% collagen) displayed the worst cell metabolic activity and cell 
number, indicating that the other variants are more suitable for supporting osteoblast 
activity. Although this study demonstrates their reduced potential for bone tissue 
engineering, these original collagen-GAG variants were used by Farrell et al [17] and 
were still able to achieve mineralisation of the scaffold when seeded with mesenchymal 
stem cells in osteogenic media.  The results from this study thus demonstrate that using 
our new optimised scaffolds, even greater levels of bone formation in vitro may be 
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achieved.  In order for osteoblasts to create bone, cells secrete an extra-cellular matrix 
(ECM) comprising type-I collagen and various bone proteins and glycosaminoglycans 
such as osteocalcin, osteopontin and chondroitin-sulphate. The ECM is then mineralised 
by the nucleation and deposition of calcium and phosphate into minerals such as 
hydroxyapatite, which gives bone its mechanical strength. Some studies have shown that 
there can be an inhibition of hydroxyapatite crystal growth in the presence of 
glycosaminoglycans and proteoglycans [33, 34]. However, other studies have found 
chondroitin-sulphate to be almost non-inhibitory in the formation of hydroxyapatite 
crystals [35]. This is promising since our 0.2% GAG construct exhibited high cell 
metabolic activity, cell number and widespread cell attachment and the interaction of the 
GAG scaffold variants.  It will therefore be interesting to evaluate the relationship 
between bone formation and the presence of increased GAG in longer term 
mineralisation investigations.  
     There were a number of limitations with this study. Although scaffold fabrication 
using the constant cooling freeze-drying technique creates a homogenous pore 
architecture [12, 36], the final collagen and GAG scaffold variants appeared to have 
differing pore sizes which can be seen from the histological images. The lower content 
collagen scaffolds demonstrated a spongy pore architecture which is markedly different 
to the higher collagen content scaffold which demonstrated elongated plates of collagen. 
It has been shown in previous studies that pore size affects material properties of the 
collagen-GAG scaffolds including permeability and porosity, as well as cell behaviour 
and the density of ligands that are available for cells to bind to [24, 28, 37]. A previous 
study in our laboratory illustrated how a range of homogenous pore sizes allowed 
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increased attachment of osteoblastic cells as the mean pore size decreased, consistent 
with hypothesis that scaffolds with a smaller pore size have a higher surface area and,
therefore, a higher ligand density.  The mean pore size of the collagen and GAG variants 
was not assessed quantitatively in this study, but it is clear that varying the amount of 
collagen and GAG content affects the pore size and surface area.
     In conclusion, the combined results indicate that osteoblast activity on collagen-GAG 
scaffolds is affected by collagen and GAG concentrations.  The results suggest that a 
collagen-GAG scaffold containing 1% collagen and 0.2% GAG scaffold is most suitable 
for bone tissue engineering. The fact that the Standard scaffold, which has had so much 
success in skin regeneration, showed the poorest results when seeded with osteoblasts 
demonstrates that in the field of tissue engineering, scaffolds must be designed with 
tissue-specific applications in mind. 
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Figure Captions
Figure 1:  Cell metabolic activity on collagen scaffold variants 
Cell metabolic activity was determined at 6, 24, 48 h and 7 d post-seeding using the 
alamarBlueTM assay. Results are expressed as % reduction of the solution (n = 10). Error 
bars represent S.D. * p < 0.019 relative to 0.38, 0.5 and 0.75% collagen groups. # p < 
0.001 relative to 6 h.  
Figure 2: Cell number on collagen scaffold variants
Cell number was determined via DNA quantification and converted to cell number using 
a standard curve. Error bars represent S. D. (n = 3 for 6, 24, 48 h and n = 7 for 7 d). * p < 
0.008 and ** p < 0.047 relative to 0.38%, 0.5% and 0.75% collagen groups. # p < 0.009 
relative to 7 d. 
Figure 3: Cell spatial distribution on collagen scaffold variants
Light-microscopic evaluation of the collagen scaffold variants retrieved after 7 days and 
stained with H&E to evaluate cell distribution: (A) 0.25% collagen, (B) 0.38% collagen, 
(C) 0.5% collagen (D) 0.75% collagen and (E) 1% collagen. Bar indicates 100 µm  
Figure 4: Cell metabolic activity on GAG scaffold variants
Cell metabolic activity was determined at 6, 24, 48 h and 7 d post-seeding using the 
alamarBlueTM assay. Results are expressed as % reduction of the solution (n = 10). Error 
bars represent S.D. * p < 0.001 relative to all other groups at all time points. ** p < 0.001 
relative to 0.05% GAG scaffold variant. # p < 0.001 relative to 6 h.
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Figure 5: Cell number on GAG scaffold variants 
Cell number was determined via DNA quantification and converted to cell number using 
a standard curve. Error bars represent S. D. (n = 3 for 6, 24, 48 h and n = 7 for 7 d). * p < 
0.003 relative to all other groups and ** p = 0.05 relative to 0.05% and 0.1% GAG 
groups. # p< 0.018 relative to 6 h.    
Figure 6: Cell spatial distribution on GAG scaffold variants
Light-microscopic evaluation of the GAG scaffold variants retrieved after 7 days and 
stained with H&E to evaluate cell distribution: (A) 0% GAG (B) 0.05% GAG (C) 0.1% 
GAG (D) 0.2% GAG. Bar indicates 100 µm  
Table 1: Porosity of collagen scaffold variants
Porosity of the dry collagen scaffold variants as calculated by the measurement of the dry 
density of each variant and solid collagen variant, using Equation 1. 
Table 2: Porosity of GAG scaffold variants
Porosity of the dry GAG scaffold variants as calculated by the measurement of the dry 
density of each variant and solid GAG variant, using Equation1. 
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Table 1
Collagen Scaffold Variants (% w/v) Relative Density (mg/mm3) Porosity (%) 
0.25% 0.010 + 3.2 x 10-3 98.99 + 0.32 
0.38% 0.005 + 3.4 x 10-4 99.52 + 0.03 
0.5% 0.007 + 1.8 x 10-3 99.26 + 0.18 
0.75% 0.010 + 9.0 x 10-4 98.96 + 0.09 
1% 0.012 + 4.0 x 10-3 98.80 + 0.06 
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Table 2
GAG Scaffold Variants (%w/v) Relative Density (mg/mm3) Porosity (%)
0% 0.006 + 5.6 x 10-4 99.41 + 0.06
0.05% 0.006 + 3.2 x 10-4 99.40 + 0.03
0.1% 0.007 + 1.9 x 10-3 99.26 + 0.19
0.2% 0.009 + 4.3 x 10-4 99.07 + 0.04
Page 28 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
0%
10%
20%
30%
40%
50%
0.25% collagen 0.38% collagen 0.5% collagen 0.75% collagen 1% collagen
Collagen Scaffold Variants
P
e
r
c
e
n
t
 
R
e
d
u
c
e
d
6 h
24 h 
48 h 
7 d 
*
*
#
#
#
Figure 1
Page 29 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
0.25 % collagen 0.38 % collagen 0.5% collagen 0.75% collagen 1% collagen
Collagen Scaffold Variants
C
e
l
l
 
N
u
m
b
e
r
6  h
2 4  h  
4 8  h  
7  d  
 *
* *
#
F i g u r e  2  
Page 30 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
d
eb
c
a
Figure 3
Page 31 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
0%
10%
20%
30%
40%
50%
0% GAG 0.05% GAG 0.1% GAG 0.2% GAG
GAG Scaffold Variants
P
e
r
c
e
n
t
 
R
e
d
u
c
e
d
6 h
24 h
48 h
7 d
*
#
#
#**
**
Figure 4
Page 32 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
3.0E+06
0 % GAG 0.05 % GAG 0.1 % GAG 0.2 % GAG
GAG Scaffold Variants
C
e
l
l
 
N
u
m
b
e
r
6 h
24 h 
48 h 
7 d 
 *
**#
Figure 5
Page 33 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
db
a c
Figure 6 
Page 34 of 34
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
